Clinical Report: A Case Study of Metaplastic Breast Carcinoma Exhibiting Osteosarcomatous Differentiation
Background
Metaplastic breast carcinoma (MBC) is a rare and aggressive form of breast cancer, accounting for less than 1% of all cases. MBC with osteosarcomatous differentiation is particularly uncommon, presenting significant challenges in diagnosis and treatment.
Data Highlights
No numerical or trial data is presented in the article.
Key Findings
MBC accounts for less than 0.2-1% of all breast cancers.
MBC with osteosarcomatous differentiation is extremely rare, comprising 0.003%-0.12% of cases.
The patient had a history of triple-negative breast cancer and underwent multiple treatment modalities.
Final pathology confirmed MBC with osteosarcomatous differentiation, showing SATB2 positivity and a Ki-67 index of 70%.
Postoperative BRCA1/2 testing was negative, and adjuvant chemotherapy combined with immunotherapy was administered.
Clinical Implications
The case illustrates the importance of thorough diagnostic assessment and the need for multimodal treatment approaches in managing MBC with osteosarcomatous differentiation. Clinicians should be aware of the aggressive nature of this cancer subtype and consider comprehensive treatment strategies.
Conclusion
This case highlights the complexities involved in diagnosing and treating metaplastic breast carcinoma with osteosarcomatous differentiation, emphasizing the need for tailored therapeutic approaches.
